Mortality

AM Best Affirms Credit Ratings of NLV Financial Corporation and Its Insurance Subsidiaries

Retrieved on: 
Thursday, June 1, 2023
Other Professional Services, Professional Services, Insurance, AM Best, ALL, ERM, NLV, Culture, COVID-19, Long-Term Capital Management, GAAP, National Life Group, Credit, Movement, Ohio National Life Insurance Company, K-12, Superior, NL, AM, Growth, Mortality, Long-term care insurance, News, Risk management, Security (finance), Palladium

Concurrently, AM Best has affirmed the Long-Term Issue Credit Ratings (Long-Term IRs) of “a” (Excellent) of the surplus notes of NLIC.

Key Points: 
  • Concurrently, AM Best has affirmed the Long-Term Issue Credit Ratings (Long-Term IRs) of “a” (Excellent) of the surplus notes of NLIC.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress

Retrieved on: 
Thursday, June 1, 2023
Health, Surgery, Other Health, General Health, Research, Science, Pharmaceutical, Abstract, Stanford University, Section, Survival, C127, Intelligence, Transplant, Congress, MD, Patient, Disease, Kidney, Heart transplantation, Artificial intelligence, Heart failure, Mortality, ATC, Immunosuppression, Caregiver, Biopsy, Dentistry

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations.

Key Points: 
  • CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 2023 American Transplant Congress (ATC) with 65 scientific presentations.
  • CareDx will also be hosting a satellite symposium1 andsponsoring the Women’s Networking Event.
  • "We are proud to showcase our leadership with our highest-ever number of abstracts at the 2023 Transplant Congress with data that not only validates the performance of AlloSure® and AlloMap® but also demonstrates their clinical utility in the surveillance and management of patients,” said Reg Seeto, CEO and President of CareDx.
  • A combination of AlloSure, serum creatinine and biopsy can improve early detection of subclinical rejection and predict graft failure (C127).

Allianz Trade 2023 Global Survey

Retrieved on: 
Thursday, June 1, 2023
Insurance, Finance, Banking, Professional Services, Supply Chain Management, Logistics, Transport, Retail, Carbon, Pressure, XI, Economy, Economic Research Institute for ASEAN and East Asia, Risk management, IX, Public policy, Cost accounting, Carbon Border Adjustment Mechanism, Virginia Tech Corporate Research Center, Small and medium-sized enterprises, VII, Allianz, COVID-19, Small, VIII, Corporation, Euler Hermes, Disease, ESG, Mortality, Health, Environment, III, AA, VI, Renewable energy, Bank

Today, Allianz Trade releases the second edition of its Global Survey.

Key Points: 
  • Today, Allianz Trade releases the second edition of its Global Survey.
  • This echoes the less favourable environment for global trade in 2023: Allianz Trade expects global trade to grow slowly in terms of volume (+0.7% vs. +3.8% in 2022) and to decline in terms of value (-0.1% vs. +9.7% in 2022).
  • This growing interest could also unlock trade financing for Small and Medium Enterprises that were previously shying away from global trade,” states Ano Kuhanathan, Head of Corporate Research at Allianz Trade.
  • We predict trade and credit risk today, so companies can have confidence in tomorrow
    Allianz Trade is the global leader in trade credit insurance and a recognized specialist in the areas of surety, collections, structured trade credit and political risk.

Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Medical Devices, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, SOFA, Infection, The Lancet, Inflammation, Septic shock, Patient, Manuscript, Mortality, Respiratory failure, Safety, COVID19, Disease, Pharmaceutical industry

The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.

Key Points: 
  • The first article presents the ASTONISH Phase 2b trial in septic shock patients and the second one the ESSENTIAL Phase 2 trial for the treatment of critically ill COVID-19 patients.
  • The findings presented further validate Inotrem’s innovative approach to treat inflammatory diseases by targeting TREM-1.
  • “Nangibotide is the first TREM-1 inhibitor and has the potential to become the first causal treatment of life-threatening immune dysregulations.
  • “We look forward to bringing this potential new treatment option to patients suffering from severe and often fatal inflammatory conditions.”

STAND UP TO CANCER ANNOUNCES $1.5 MILLION COMMITMENT FROM PANCREATIC CANCER NORTH AMERICA TO FUND PANCREATIC CANCER VACCINE RESEARCH

Retrieved on: 
Thursday, June 1, 2023
Vaccine, Messenger RNA, Memorial Sloan Kettering Cancer Center, Pancreatic cancer, Convergence research, COVID-19, Cancer, Hope, Research, Doctor of Philosophy, Messenger, Collaborative RESearch Team to study psychosocial issues in Bipolar Disorder, MD, Patient, Immune system, SU2C, MSK, Mortality, PCNA, Pharmaceutical industry

The vaccine developed for the trial was tailored to recognize the cancer cells present in each trial participant's pancreatic cancer tumor and stimulate the body's immune system to fight the cancer.

Key Points: 
  • The vaccine developed for the trial was tailored to recognize the cancer cells present in each trial participant's pancreatic cancer tumor and stimulate the body's immune system to fight the cancer.
  • "We are delighted to be collaborating with Stand Up To Cancer to fund the future of this ground-breaking research.
  • The outcome of this study could represent a real turning point for pancreatic cancer," said Michelle Capobianco, president and CEO, Pancreatic Cancer North America.
  • "Pancreatic cancer research is a significant focus for SU2C, accounting for over 23% of our entire cancer portfolio.

DELFI Diagnostics Hires David Morgenstern, PhD, as Vice President of Clinical Development

Retrieved on: 
Thursday, June 1, 2023
Oncology, Therapy, Public, PALO, DELFI, Cancer, Drug, Dave's Markets, Doctor of Philosophy, Novartis, MD, Merck, Immunology, Mortality, Endocyte, Medical imaging, Indiana University, Microbiology, Genetics

BALTIMORE and PALO ALTO, Calif., June 1, 2023 /PRNewswire/ -- DELFI Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Dave Morgenstern, PhD, as Vice President of Clinical Development.

Key Points: 
  • BALTIMORE and PALO ALTO, Calif., June 1, 2023 /PRNewswire/ -- DELFI Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Dave Morgenstern, PhD, as Vice President of Clinical Development.
  • Dave joins DELFI from Roche Diagnostics, where he spent more than a decade in clinical development roles focused on oncology screening and diagnostic products, most recently as Global Head of Clinical Development for Oncology and Genetics.
  • "I am very excited to add Dave's experience developing oncology diagnostics and therapeutics to DELFI's leadership team," said Victor Velculescu, MD, PhD, DELFI's Founder and CEO.
  • "I am excited to help develop the clinical evidence that will support the DELFI platform's use in multiple applications."

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Retrieved on: 
Thursday, June 1, 2023
Columbia University, Columbia University Irving Medical Center, Maxident, Lightning, FRCS, Amputation, ALI, Quality of life, CIS, Artery, Libin Cardiovascular Institute, Friction, MD, Patient, Physician, FACS, Buerger's test, Mortality, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Food, Pharmaceutical industry, Birth control

Lightning Bolt 7 introduces a new method for removing blood clots, modulated aspiration, which pairs Penumbra's Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm.

Key Points: 
  • Lightning Bolt 7 introduces a new method for removing blood clots, modulated aspiration, which pairs Penumbra's Lightning Intelligent Aspiration technology with an advanced microprocessor algorithm.
  • When used together, Lightning Bolt 7 is designed to enhance the ability to rapidly remove large, fibrous blood clots in the arteries with minimal blood loss, addressing conditions such as acute limb ischemia (ALI), hibernating thrombus and visceral occlusions.
  • "Advancements like Lightning Bolt 7 provide a critical frontline option for physicians to treat patients and improve patient outcomes."
  • Powered by the Penumbra ENGINE®, Lightning Bolt 7 is engineered to detect the difference between blood clot and blood flow.

The Iconic Xenomorph sculpture that inspired Ridley Scott's 'Alien' film series to be sold as 500 digital pieces on June 16th

Retrieved on: 
Wednesday, May 31, 2023
Monte-Carlo Pavilions, Love, Banksy, Sculpture, Horror fiction, Love Is in the Air, Sale, Ridley Scott, Metamorphoses, Atmosphere of Earth, Collection, Xenomorph, Academy Awards, Alien, Mortality, Mike Winkelmann, Film industry, Particle

NEW YORK , May 31, 2023 /PRNewswire/ -- Particle, a digital fine-art platform and tokenizer of Banksy's 'Love is in the Air' painting, will give art collectors the chance to obtain digital pieces of the Xenomorph/Alien III sculpture from renowned artist, H.R Giger, the Academy Award winner behind the iconic Xenomorph design from Ridley Scott's Sci-fi horror film franchise, Alien. The genre-defining sculpture is being 'tokenized' into 500 separate parts which will go on sale on June 16th on the Particle website.

Key Points: 
  • The genre-defining sculpture is being 'tokenized' into 500 separate parts which will go on sale on June 16th on the Particle website .
  • It has been exhibited at prominent art centers such as the ICA Miami and Praz-Delavallade Gallery in LA.
  • Co-owners will obtain subsequent voting rights on whether to sell the sculpture, should an offer be made on it.
  • They will also be loaning the sculpture to the Particle Foundation, who will tour the work around the world.

The Iconic Xenomorph sculpture that inspired Ridley Scott's 'Alien' film series to be sold as 500 digital pieces on June 16th

Retrieved on: 
Wednesday, May 31, 2023
Monte-Carlo Pavilions, Love, Banksy, Sculpture, Horror fiction, Love Is in the Air, Sale, Ridley Scott, Metamorphoses, Atmosphere of Earth, Collection, Xenomorph, Academy Awards, Alien, Mortality, Mike Winkelmann, Film industry, Particle

NEW YORK, May 31, 2023 /PRNewswire/ -- Particle, a digital fine-art platform and tokenizer of Banksy's 'Love is in the Air' painting, will give art collectors the chance to obtain digital pieces of the Xenomorph/Alien III sculpture from renowned artist, H.R Giger, the Academy Award winner behind the iconic Xenomorph design from Ridley Scott's Sci-fi horror film franchise, Alien. The genre-defining sculpture is being 'tokenized' into 500 separate parts which will go on sale on June 16th on the Particle website.

Key Points: 
  • The genre-defining sculpture is being 'tokenized' into 500 separate parts which will go on sale on June 16th on the Particle website .
  • It has been exhibited at prominent art centers such as the ICA Miami and Praz-Delavallade Gallery in LA.
  • Co-owners will obtain subsequent voting rights on whether to sell the sculpture, should an offer be made on it.
  • They will also be loaning the sculpture to the Particle Foundation, who will tour the work around the world.

Digital Health Start-up, Metronomic, Working on improving outcomes in pregnancy care through their platform Materno™

Retrieved on: 
Tuesday, May 30, 2023
Pressure, Insurance, Pregnancy, Femtech, Gestational diabetes, OBGYN, Woman, MBA, Mother, Metronomic therapy, Patient, Risk, Pre-eclampsia, Mortality, Death, Dietary supplement, Nursing, Juan Materno Vásquez de León

Materno™ is a digital platform that gives mothers access to OBGYNs, human care managers, remote monitoring, telehealth and other insightful features that allow them to take charge of their pregnancy.

Key Points: 
  • Materno™ is a digital platform that gives mothers access to OBGYNs, human care managers, remote monitoring, telehealth and other insightful features that allow them to take charge of their pregnancy.
  • Firstly, they provide customized and personalized care plans that align with clinical evidence and are supported by AI-powered predictions.
  • This increases the likelihood of complications being identified earlier to safeguard pregnant mothers and their babies, from common health issues typically associated with pregnancy.
  • Thirdly, the platform helps eliminate preventable complications costs and reduces the overall costs of care for pregnant mothers and for insurance companies.